Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis-Reference-Cited by-同舟云学术

Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis

Published:2019-05-01 Issue:5 Volume:76 Page:536
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Harding Katharine¹²³,Williams Owain¹²,Willis Mark¹²,Hrastelj James¹²,Rimmer Anthony³,Joseph Fady³,Tomassini Valentina¹²,Wardle Mark²,Pickersgill Trevor²,Robertson Neil¹²,Tallantyre Emma¹²

Affiliation:

1. Institute of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom

2. Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales, Heath Park, Cardiff, United Kingdom

3. Department of Neurology, Royal Gwent Hospital, Newport, United Kingdom

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

http:///jamaneurology/article-pdf/76/5/536/17579728/jamaneurology_harding_2019_oi_180112.pdf

Reference27 articles.

1. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.;Shirani;JAMA,2012

2. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.;Palace;Lancet Neurol,2015

3. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.;Tilling;Health Technol Assess,2016

4. Long-term evolution of multiple sclerosis disability in the treatment era.;Cree;Ann Neurol,2016

5. Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis.;Greenberg;JAMA Neurol,2013

Cited by 228 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study;Multiple Sclerosis and Related Disorders;2024-10

2. Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments;Journal of Central Nervous System Disease;2024-09-13

3. Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness;Neurological Sciences;2024-09-11

4. A future of AI-driven personalized care for people with multiple sclerosis;Frontiers in Immunology;2024-08-19

5. Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-08